Trial
MOVE-Lp(a) (muvalaplin outcomes)
Status Recruiting, primary completion March 2031
The first outcomes trial of an oral Lp(a)-lowering drug: 10,450 adults with elevated Lp(a) who have had a prior ASCVD event or are at risk of a first one, randomised to daily muvalaplin or placebo; MACE endpoint. Started September 2025, primary completion expected March 2031.
Mechanism. Muvalaplin is a small molecule that blocks the assembly of apo(a) with apoB100 while sparing plasminogen; it lowers Lp(a) by 82 to 86 percent on an intact-particle assay (KRAKEN, JAMA 2025). Because the traditional apo(a)-based assay detects free apo(a), it under-reads muvalaplin's effect (about 70 percent), a measurement point that will matter when reading the trial.
oral inhibitionoraloutcomes trialphase 3
Page updated 17 August 2026.